Esophageal Cancer Clinical Trials in Houston, Texas

23 studies are recruiting for esophageal cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   5 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

2. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, Houston, Texas

   Locations

   54 in total

   Run by

   Genmab

   See if you can join NCT03526835 on ClinicalTrials.gov

3. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   16 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

4. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   96 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

6. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

   The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Houston, Texas

   Locations

   314 in total

   Run by

   AstraZeneca

   See if you can join NCT07431281 on ClinicalTrials.gov

7. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

8. A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

   The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center (Data Collection Only), Houston, Texas

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06123338 on ClinicalTrials.gov

9. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, Houston, Texas

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

10. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    31 in total

    Run by

    Pfizer

    See if you can join NCT07090499 on ClinicalTrials.gov

11. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center ( Site 6920), Houston, Texas

    Locations

    50 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06469944 on ClinicalTrials.gov

12. Pan-tumor MRD Study

    The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, f…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston, Texas

    Locations

    47 in total

    Run by

    Paradigm Health

    See if you can join NCT06605404 on ClinicalTrials.gov

13. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Oncology Consultants, P.A., Houston, Texas

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

14. Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

    This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center ( Site 8920), Houston, Texas

    Locations

    46 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06445972 on ClinicalTrials.gov

15. IDOV-Immune for Advanced Solid Tumors

    This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    5 in total

    Run by

    ViroMissile, Inc.

    See if you can join NCT06910657 on ClinicalTrials.gov

16. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    28 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

17. Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

    To learn how radiation treatment may affect your responses to vaccines against pneumonia.

    Stage

    Not phased

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06181656 on ClinicalTrials.gov

18. 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

    To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06414902 on ClinicalTrials.gov

19. The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

    The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpos…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Md Anderson Cancer Center, Houston, Texas

    Locations

    18 in total

    Run by

    UMC Utrecht

    See if you can join NCT04075305 on ClinicalTrials.gov

20. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

    This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Baylor St. Luke's Medical Center, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT03740256 on ClinicalTrials.gov

21. A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

    The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors. The main objectives of this study are : * To Determine the maximum tolerated dose (MTD) and recommended dose for expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Oncology Consultants, Houston, Texas

    Locations

    7 in total

    Run by

    Phrontline Biopharma

    See if you can join NCT07181473 on ClinicalTrials.gov

22. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    The University of Texas MD Anderson Cancer Center (site 127), Houston, Texas

    Locations

    15 in total

    Run by

    VM Oncology, LLC

    See if you can join NCT03556228 on ClinicalTrials.gov

23. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    6 in total

    Run by

    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov